STOCK TITAN

CORCEPT THERAPEUTICS (CORT) SEC Filings

CORT NASDAQ

Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.

The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.

Rhea-AI Summary

Corcept Therapeutics Inc. director Daniel N. Swisher Jr. exercised options to acquire 1,100 common shares at $14.0800 per share and 400 shares at $10.5000 per share on November 10, 2026, and reported a sale of 1,500 common shares at $74.0700 per share that day. The sale was made pursuant to a Rule 10b5-1 plan adopted August 3, 2026; both options were fully exercisable. A footnote to the 400-share option says he previously transferred 12,500 shares underlying the option to his ex-spouse and no longer reports securities owned by her as beneficially owned.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Corcept Therapeutics Inc. director Daniel Swisher Jr. reported a proposed sale of 1,500 common shares, with an aggregate market value of $112,537.50 and an approximate sale date of November 10, 2026. The shares were acquired from the issuer on November 10, 2026 through an exercise of stock options, with cash payment. The proposed sale has an associated August 3, 2026 adoption or instruction date under Rule 10b5-1; Morgan Stanley Smith Barney LLC is the named broker.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
other
-
Rhea-AI Summary

Corcept Therapeutics Inc. reporting person Sean Maduck, identified as former President, Corcept Endocrinology, exercised options and sold common shares. On November 2, 2026, he exercised 11,841 options at $8.27 per share and sold 11,841 shares at a weighted-average price of $81.4183 per share. On November 3, 2026, he exercised 13,159 options at $8.27 per share and sold 8,617 shares at a weighted-average $82.0198 and 4,542 shares at a weighted-average $82.6756 per share. The sales were made under a Rule 10b5-1 plan adopted December 8, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.58%
Tags
insider
Rhea-AI Summary

Roberto Wandenkolk Vieira, Corcept Therapeutics Inc.'s President, Oncology, exercised options covering 8,333 common shares on November 2, 2026, at $21.63 per share. He also sold 8,333 shares in two transactions: 6,657 at a weighted average of $80.7326 per share and 1,676 at $81.5226 per share. Both sales were made under a Rule 10b5-1 plan adopted June 17, 2026, before he became an officer. The reported option position after exercise was 125,001 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.58%
Tags
insider
-
Rhea-AI Summary

Corcept Therapeutics Incorporated reported third-quarter 2026 net product revenue of $340.472 million, compared with $207.638 million a year earlier, and net income of $126.778 million, versus $19.668 million. Hypercortisolism Products generated $249.067 million and Lifyorli generated $91.405 million. Lifyorli sales began in April after its March FDA approval with nab-paclitaxel for platinum-resistant ovarian cancer.

For the nine months ended September 30, 2026, product revenue was $761.522 million versus $559.282 million, and operating cash flow was $159.662 million versus $103.548 million. Cash, cash equivalents and marketable securities totaled $662.3 million as of September 30, 2026. Corcept expects 2026 research and development expense to be approximately the same as in 2025 and selling, general and administrative expense to be higher.

After the FDA requested additional analyses of relacorilant data, Corcept resubmitted its NDA on June 17, 2026; the FDA's review target date is December 17, 2026. The DAZALS trial did not meet its primary endpoint, although Corcept reported exploratory survival analyses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
quarterly report
-
Rhea-AI Summary

Corcept Therapeutics Incorporated (CORT) reported third-quarter 2026 revenue of $340.5 million, up 64% from the same period in 2025, and net income of $126.8 million, compared with $19.7 million. Diluted net income per common share was $1.01 versus $0.16. Korlym and authorized generic revenue was $249.1 million; Lifyorli revenue was $91.4 million. Corcept reiterated 2026 revenue guidance of $1.1–$1.2 billion. Cash and investments were $662.3 million at September 30, 2026, compared with $544.6 million at June 30, 2026.

In BELLA Part A, a Phase 2 trial in 95 patients with platinum-resistant ovarian cancer, relacorilant plus nab-paclitaxel and bevacizumab had median progression-free survival of 7.2 months, objective response rate of 59%, and 88% overall survival at six months; median overall survival had not been reached at primary analysis. The EMA's CHMP recommended approval of the combination, with European Commission approval expected by the end of this year. Corcept's resubmitted Cushing's syndrome NDA has a December 17, 2026 PDUFA date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
current report
Rhea-AI Summary

BlackRock, Inc. reported beneficial ownership of 9,614,217 shares of Corcept Therapeutics Incorporated (CORT) common stock, equal to 8.9% of the class, in its September 30, 2026 ownership report. BlackRock reported sole voting power over 9,288,025 shares and sole dispositive power over 9,614,217 shares, with no shared voting or dispositive power. The reported position reflects securities attributed to certain BlackRock business units and excludes securities, if any, held by other business units whose beneficial ownership is disaggregated.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.50%
Tags
ownership
-
Rhea-AI Summary

Corcept Therapeutics Inc. (CORT) director James N. Wilson reported that the James N. Wilson and Pamela D. Wilson Trust sold 10,000 common shares on October 15, 2026: 6,654 shares at a weighted average price of $114.4751 per share, 3,046 at $115.3895, and 300 at $116.2967. The sales were made under a Rule 10b5-1 plan adopted by Wilson on March 12, 2026.

Wilson has voting power over shares held by the selling trust and disclaims beneficial ownership except to the extent of his pecuniary interest. Separate indirect holding entries list 200,000 shares in each of the James N. Wilson 2025 Grantor Retained Annuity Trust and Pamela D. Wilson 2025 Grantor Retained Annuity Trust.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
insider
-
Rhea-AI Summary

Corcept Therapeutics' President, Oncology, Roberto Wandenkolk Vieira, exercised options for 8,333 common shares at $21.63 per share on October 2, 2026. The reported stock-option position after the exercise was 133,334 shares.

Three common-stock sales were reported that day: 1,100 shares at a weighted average of $114.5205 per share, 2,086 at $115.7298, and 5,147 at $116.5850. The sales were made under a 10b5-1 plan adopted June 17, 2026, before he was appointed an officer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
insider
Rhea-AI Summary

Corcept Therapeutics Chief Accounting & Technology Officer Joseph Douglas Lyon exercised options for 810 shares at $13.56 per share on October 1, 2026, and for 3,357 shares at $13.56 and 5,833 shares at $19.26 on October 2, 2026. He sold 810 shares at a weighted-average $115.3985 per share on October 1, 2026, and sold 4,446 shares at $115.6970 and 4,744 shares at $116.5407 per share on October 2, 2026. The sales were made under a Rule 10b5-1 plan adopted June 10, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
insider

FAQ

How many CORCEPT THERAPEUTICS (CORT) SEC filings are available on StockTitan?

StockTitan tracks 201 SEC filings for CORCEPT THERAPEUTICS (CORT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for CORCEPT THERAPEUTICS (CORT)?

The most recent SEC filing for CORCEPT THERAPEUTICS (CORT) was filed on November 13, 2026.